EPIX Pharmaceuticals to Present at the Alzheimer's Association Research Roundtable Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct 16, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that J. Thomas Megerian, M.D., Ph.D., executive director for clinical development at EPIX, is scheduled to participate in a session entitled, "Strategy for Trial Design for Treatments with Potential Symptomatic and Disease Modifying Effects: Program Development Issues II" at the Alzheimer's Association Research Roundtable: Optimal Trial Design for Disease Modifying Therapies in Alzheimer's Disease meeting in Washington, D.C., on Tuesday, October 21, 2008 at 9:30 a.m. (ET).
Dr. Megerian's presentation will focus on the company's clinical trial experience with PRX-03140 a novel, highly selective, 5-HT4 agonist being developed for the treatment of Alzheimer's disease. In May 2008, EPIX announced the initiation of a Phase 2b proof-of-concept program for PRX-03140 that consists of two clinical trials - a six-month trial evaluating PRX-03140 in combination with donepezil and a three-month trial studying PRX-03140 as monotherapy. PRX-03140 is part of EPIX's strategic partnership with GlaxoSmithKline.
About the Alzheimer's Association Research Roundtable
Convened by the Alzheimer's Association in 2003, the Alzheimer's Association Research Roundtable is a consortium of Association staff and advisors along with scientists from the pharmaceutical, biotech, imaging and cognitive testing industries. The consortium also invites thought leaders and guest representatives from academic institutions and government regulatory agencies to appropriate meetings. The mission of the Research Roundtable is to facilitate the development and implementation of new treatments for Alzheimer's disease by collectively addressing obstacles to research and development, clinical care and public health education.
About the GSK CEEDD
GlaxoSmithKline is enhancing the way it discovers and develops drugs by creating a small dedicated team who will feed the GSK pipeline through the efforts of its external collaborations. In essence, the CEEDD (Center of Excellence for External Drug Discovery) will 'virtualize' a portion of the GSK pipeline; namely, from Target to Clinical PoC, by forming multiple risk-sharing/reward-sharing alliances.
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen and Cystic Fibrosis Foundation Therapeutics.
This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Kim C. Drapkin, 781-761-7602
Chief Financial Officer
Jennifer Beugelmans, 646-596-7473
Posted: October 2008